Based on the Entrada Therapeutics Inc stock forecast from 3 analysts, the average analyst target price for Entrada Therapeutics Inc is USD 23.60 over the next 12 months. Entrada Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Entrada Therapeutics Inc is Slightly Bullish , which is based on 8 positive signals and 4 negative signals. At the last closing, Entrada Therapeutics Inc’s stock price was USD 18.45. Entrada Therapeutics Inc’s stock price has changed by -10.04% over the past week, +3.36% over the past month and +26.89% over the last year.
No recent analyst target price found for Entrada Therapeutics Inc
No recent average analyst rating found for Entrada Therapeutics Inc
Company Overview Entrada Therapeutics Inc
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. Read Less
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therap...Read More
Frequently Asked Questions About Entrada Therapeutics Inc (TRDA) Stock
Based on ratings from 3 analysts Entrada Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on TRDA's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for TRDA is USD 23.60 over the next 12 months. The maximum analyst target price is USD 29 while the minimum anlayst target price is USD 18.
TRDA stock's Price/Earning ratio is 12.26.
Our analysis grades TRDA stock's Price / Earning ratio at F. This means that TRDA stock's Price/Earning ratio is above 60% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this TRDA may be a overvalued for its sector.
The last closing price of TRDA's stock was USD 18.45.
The most recent market capitalization for TRDA is USD 0.66B.
Based on targets from 3 analysts, the average taret price for TRDA is projected at USD 23.60 over the next 12 months.
This means that TRDA's stock price may go up by +27.91% over the next 12 months.
We can't find any ETFs which contains Entrada Therapeutics Inc's stock.
As per our most recent records Entrada Therapeutics Inc has 177 Employees.
Entrada Therapeutics Inc's registered address is One Design Center Place, Boston, MA, United States, 02210.
You can get more information about it from Entrada Therapeutics Inc's website at https://www.entradatx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Entrada Therapeutics Inc (TRDA) Stock
Based on ratings from 3 analysts Entrada Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on TRDA's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for TRDA is USD 23.60 over the next 12 months. The maximum analyst target price is USD 29 while the minimum anlayst target price is USD 18.
TRDA stock's Price/Earning ratio is 12.26.
Our analysis grades TRDA stock's Price / Earning ratio at F. This means that TRDA stock's Price/Earning ratio is above 60% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this TRDA may be a overvalued for its sector.
The last closing price of TRDA's stock was USD 18.45.
The most recent market capitalization for TRDA is USD 0.66B.
Based on targets from 3 analysts, the average taret price for TRDA is projected at USD 23.60 over the next 12 months.
This means that TRDA's stock price may go up by +27.91% over the next 12 months.
We can't find any ETFs which contains Entrada Therapeutics Inc's stock.
As per our most recent records Entrada Therapeutics Inc has 177 Employees.
Entrada Therapeutics Inc's registered address is One Design Center Place, Boston, MA, United States, 02210.
You can get more information about it from Entrada Therapeutics Inc's website at https://www.entradatx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TRDA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
